Blog

  • Two Sigma Co-Founder Talks US Manufacturing at Fireside Chat

    Two Sigma Co-Founder Talks US Manufacturing at Fireside Chat

    Revitalizing American manufacturing has been at the center of political and economic discourse — and presidential campaigns — for decades. David Siegel thinks he has an answer: Start paying more attention to our physical world and less on the virtual one.

    Northeastern University President Joseph E. Aoun recently sat down with Siegel — a computer scientist, philanthropist and co-founder of tech-focused financial services company Two Sigma — to discuss everything from revitalizing American industry and infrastructure to artificial intelligence and next steps for higher education. 

    The world of higher education will play a vital role in the revitalization, Siegel says. Partnerships between private industry and academic institutions are more necessary than ever, not only to train the next generation of innovators but also to provide them with the resources and space to pursue entrepreneurial endeavors in high-need sectors in the U.S., such as advanced manufacturing.

    “Higher ed, like everything else in society, has to evolve, and it has evolved. Northeastern is an example of innovation in higher education. There’s a lot of money to be made, actually, by refocusing on these challenges, but it has to start with the education because who’s going to do it if no one graduates with an itch and the right skillset with an understanding of what the industry problems are?” Siegel told Aoun during a fireside chat in Northeastern’s ISEC Auditorium.

    The solutions to many of our most pressing problems — housing, food, transportation — won’t be solved by AI but by everyone pitching in, Siegel says.

    “It really comes from a thousand shining lights,” he says.

    Endeavors like jumpstarting American advanced manufacturing or things like semiconductors face deficits in workforce and know-how, both of which have gone abroad. 

    “What’s needed is everything, and everyone can do their part,” Siegel says. “Northeastern and other institutions can partner with industry to improve the workforce. The government can do certain kinds of things. Hopefully, the youth of America will want to devote their careers to it. They’ll hopefully do the thing that people do with software: They’ll create startups.”

    However, universities have to be more open to their faculty and students starting businesses and entrepreneurial ventures in the first place, Aoun adds.

    “Many of our faculty have launched various companies, and also some of these have been incubated here in the labs, and we really foster that,” Aoun explains.

    All of that work will be a generation-spanning project but one that Siegel views as vital if the U.S. wants to solve some of its most challenging problems. For a generation, Siegel says, the U.S. “has ignored physical world problems from shipbuilding to building infrastructure of all kinds, any kind of manufacturing problem” in favor of pursuing innovation in tech that remains rooted in the virtual world.

    Although Siegel expresses skepticism about AI — “it’s in the virtual world, our problems are in the physical world,” he says — he admits that AI tools will become turbochargers for academic research in a way that could produce physical world solutions. As a result, Siegel founded the Open Athena Project last year to help provide academic researchers with private-industry-caliber AI software engineers to fill a gap that exists in higher education.

    Siegel and Aoun both agreed that, despite some anxieties about AI replacing entry-level jobs, these tools could instead raise the standard for what an entry-level job is in the first place. That, in turn, could raise the caliber of students who are coming out of universities and provide an even more skilled workforce downstream.

    “Essentially, entry-level jobs are no longer going to be entry-level jobs,” Aoun says. “They’re going to be second level, which is good.”

    To address the challenges Siegel discussed, the solutions have to start with education. That means not only evolving higher education but learning from global leaders across industries, Aoun says.

    The conversation was the final piece of a daylong leadership retreat focused on Northeastern’s priorities across teaching and research, with a particular emphasis on the university’s artificial intelligence strategy.

    University News

    Recent Stories

    Continue Reading

  • UAH researchers use X-rays from quasars to answer one of the three major questions in cosmology: where are the missing baryons?

    UAH researchers use X-rays from quasars to answer one of the three major questions in cosmology: where are the missing baryons?

    BYLINE: Russ Nelson

    Researchers at The University of Alabama in Huntsville (UAH), a part of The University of Alabama System, have published a series of two papers in the Monthly Notices of the Royal Astronomical Society that resolve one of three major outstanding puzzles in cosmology: the “missing baryon problem,” a discrepancy between the amount of baryonic matter detected from shortly after the Big Bang when compared with recent epochs. Dr. Massimiliano “Max” Bonamente, a professor of physics and astronomy, along with Dr. David Spence and international colleagues, used X-ray radiation from quasars to determine the “missing” particles reside in the warm-hot intergalactic medium, or WHIM, a state of matter characterized by low density and high temperatures.

    “This is the result of over 10 years of work at UAH, primarily by myself and a recent graduate of ours, David Spence, also in collaboration with several scientists worldwide,” Bonamente says. “With three major problems in modern cosmology – missing baryons, identification of dark matter, identification of dark energy – it’s case closed on the first.”

    Baryons are subatomic particles, most commonly protons and neutrons, that comprise the bulk of visible matter in the universe. The WHIM is a crucial component of the cosmic web, the large-scale structure of the universe composed of enormous filaments of dark matter and gas that connect galaxies to one another.

    “The universe is believed to start off as a ‘ball of fire,’ the Big Bang; it then cools and forms structures on various scales: stars, galaxies, filaments of galaxies,” Bonamente notes. “The gas is attracted by the gravity of these filaments that stretch hundreds of millions of light-years, and the gas heats back up as it falls towards the WHIM. This is something any graduate student in physics would learn in their classical dynamics course, so astronomers were confident in this simple picture.”

    Current observations suggest baryons make up about five percent of the total energy density of the universe. Yet, a significant fraction of present-day baryons remained unaccounted for in deep far-ultraviolet (FUV) searches. A census of baryons in the recent observable universe found that the observed baryonic matter accounts for about one half the expected amount.

    “The location of the missing baryons near these WHIM structures was proposed back in 1999 in a seminal paper by Princeton scientists, and then consistently seen ever since in all subsequent simulations,” the researcher says. “But simulations aren’t real, and we needed to look in the real, uppercase Universe.”

    To accomplish this, Bonamente, Spence and their colleagues analyzed X-ray sources from the European Space Agency’s orbiting X-ray telescope XMM-Newton and NASA’s Chandra Observatory to augment the FUV findings to make the breakthrough.

    The core of the discovery lies in studying the cosmological density of missing baryons by analyzing X-ray absorption lines in quasars, focusing on the warm-hot intergalactic medium. In quasars, X-ray absorption lines arise when X-rays emitted from the quasar’s central black hole pass through intervening gas clouds, either within the quasar’s host galaxy or even farther away in the intergalactic medium

    Staying grounded

    The study made a systematic search for the absorption lines of highly ionized oxygen atoms in the spectra of 51 XMM-Newton and Chandra background quasars. These show up as “dark lines” in the X-ray spectrum, created when specific wavelengths are absorbed by atoms in the gas. By learning the properties of these absorption lines, like their strength and velocity, astronomers can learn about the physical conditions and amount of the absorbing gas.

    “For nearly 20 years, astronomers used a single source – or a few at most – to study this effect. This results in a strong bias of results, and the problem that one source (or few) are not representative of the whole universe,” Bonamente notes. “So, we wanted to amend that problem, and the only way to do it is to go ‘big’ with the largest sample we could come up with. Statistics demands a large sample in order to make the best possible estimates, so we did just that.”

    The results of this analysis contributes to the characterization of the missing baryons, indicating they are associated with the high–temperature portion of the WHIM, and possibly with large-scale WHIM filaments traced by galaxies, as predicted by numerical simulations and by other independent probes.

    “It is only in X-rays that the relevant absorption lines occur,” Bonamente says. “This is something that is dictated by the atomic structures. The calculations of the wavelengths where the absorption lines occur – precisely in X-rays – are reliable, and make use of standard quantum-mechanics calculations that have been confirmed in our laboratories. So, we had no other choice: hot gas at those temperatures are only ‘visible’ in X-rays.”

    Looking to the future of this research, Bonamente says there are still plenty of questions to answer.

    “There is work to do to improve the characterization of the WHIM and the missing baryons,” the researcher says. “What is exactly the temperature of the WHIM? How do these baryons distribute in the cosmos – closer to galaxy clusters or more in the intergalactic space? Are they rich in ‘metals’ or mostly hydrogen and helium? Answers to these questions will reduce the error bars on our measurements.”

    With regards to solving the big challenges in cosmology in general, Bonamente likes to take a well-grounded approach.

    “The other problems in cosmology are more speculative, in my opinion, and it may even be that there is no dark matter or dark energy after all. But it’s good to know that the ordinary matter is as it should be. Cosmologists – and many other scientists – like to look at headline-grabbing, but speculative topics such as dark energy, when in fact there are problems more down-to-earth – pun intended – that need to be solved first. Wouldn’t you want to make sure your shoelaces are tied before you run the 100 meters at the Olympics?”

    Bonamente adds that an effort of this magnitude could not be done without the support of many other dedicated scientists who bought into the idea and shared in the hard work.

    “Throughout the years, I’ve had the good fortune of being surrounded by great colleagues who made this project happen,” the researcher concludes. “It’s my pleasure to thank and acknowledge Drs. Jussi Ahoranta and Kimmo Tuominen from Helsinki University, Dr. Natasha Wijers of Northwestern University and Dr. Jelle de Plaa of SRON Utrecht, who co-authored the papers describing these findings. And my good friend Dr. Jukka Nevalainen, who has also been a long-term collaborator on this and many other projects.”



    Continue Reading

  • Economies of Love. Part 5: Commodified Life – Events

    Economies of Love. Part 5: Commodified Life – Events

    Join us on Tuesday, September 23, 2025 at e-flux Screening Room for the fifth installment in the series Economies of Love, presenting Jean-Luc Godard’s Two or Three Things I Know About Her (1967) preceded by Mako Idemitsu’s Kiyoko’s Situation (1989). 

    Two or Three Things I Know About Her follows Juliette, a Parisian woman navigating middle-class suburban life in 1960s France. Advertising images and consumer infrastructures script her routine; housework, shopping, childcare, and occasional sex work are driven by the same logic of economic transaction. Meanwhile, Kiyoko’s Situation focuses on Kiyoko, a Japanese painter, whose creativity has been stifled by years of self-sacrifice to norms imposed on married women in modern Japan. Kiyoko is portrayed as an immobilized woman. A TV monitor within the frame replays her domestic tasks—shopping, laundry, pouring milk, serving tea—while the visages of her mother and mother-in-law on the screen admonish her to sacrifice art for family. 

    While Godard shows how the bodies of women are compromised when societal expectations are organized by advertisement logic where intimacy is converted into transactional value, Idemitsu exposes how patriarchy normalizes the division of labor and devalues artistic work when it yields no immediate profit. Both works cast a critical eye on late-capitalist metrics of worth based on fake equivalence between personal and economic desires, and show how mass mediation does not merely reflect the commodification of life but helps to produce and regulate it.

    Economies of Love is a series that examines how love is shaped by labor, technology, and power—structured by economies of care and exchange, mediated through digital and urban infrastructures, and regulated by shifting social and political contexts—while also being a force for subversion and transformation within these very structures. More information and an archive of previous screenings can be found here.

    Films

    Mako Idemitsu, Kiyoko’s Situation (1989, 24 minutes)
    Kiyoko’s Situation articulates the deeply embedded cultural roles of Japanese women through the parallel stories of two female artists, Kiyoko and Tani. In Idemitsu’s narrative-within-a-narrative, Kiyoko’s “situation” is played out on a television monitor within Tani’s drama. Tani is paralyzed in her attempts to paint by her feeling that, as a single woman, she has failed in society’s eyes. Kiyoko, a young mother viciously criticized by her husband and family for her fierce determination to paint, eventually compromises her art for “maternal duty.” As Kiyoko complies with the family, Tani, isolated and despairing, is driven to suicide. Idemitsu’s chillingly omniscient television monitor, which acts as the psychological “other,” metaphorically and literally condemns Tani to death. In the final cruel irony, she hangs herself, using the television monitor as a jumping-off point.

    Jean-Luc Godard, Two or Three Things I Know About Her (1967, 87 minutes)
    Godard’s portrait of Paris in the 1960s follows Juliette, a young mother in the suburbs who supplements her homemaking by engaging in sex work. Derived from a newspaper report about housewives in the new vast housing projects around Paris, the film is a lyrical, self-reflexive, philosophical examination of both mass media and consumer society in the mid-60s. Juliette’s intimate life becomes a site of economic exchange—shopping, child-rearing, and clandestine encounters—blurring natural affection with transactional relations. 

    For more information, contact program [​at​] e-flux.com.

    Accessibility
     – Two flights of stairs lead up to the building’s front entrance at 172 Classon Avenue.
     – For elevator access, please RSVP to program [​at​] e-flux.com. The building has a freight elevator nearest to 180 Classon Ave (garage door) leading into the e-flux office space. A ramp is available for steps within the space.
     – e-flux has an ADA-compliant bathroom with no steps between the event space and this bathroom.

    Continue Reading

  • Round of 16: Pairings, tip-off times confirmed for September 6 games

    Round of 16: Pairings, tip-off times confirmed for September 6 games

    The official EuroBasket app

    RIGA (Latvia) – The pairings and tip-off times for the first set of Round of 16 games on Saturday, September 6 have now been confirmed.

    The Group Phase action in Riga, Latvia (Group A) and Tampere, Finland (Group B) reached its conclusion on Wednesday, with the two groups crossing over as eight advance to the Final Phase.

    Stay up to date on the Final Phase teams

    Tracker: Who is qualified for the Round of 16?

    The Round of 16 matchups, and timings, are as follows:

    Saturday, September 6

    Türkiye vs Sweden – 12:00 local (11:00 CET)
    Germany vs Portugal – 15:15 local (14:15 CET)
    Lithuania vs Latvia – 18:30 local (17:30 CET)
    Serbia vs Finland – 21:45 local (20:45 CET)

    The remaining pairings for the Round of 16 will be confirmed on Thursday when the action concludes in Groups C and D in Limassol, Cyprus and Katowice, Poland.

    FIBA

    Continue Reading

  • XAI CFO Mike Liberatore Leaves Three Months After Taking Job

    XAI CFO Mike Liberatore Leaves Three Months After Taking Job

    XAI Chief Financial Officer Mike Liberatore has left the company just a few months after taking the job, according to people familiar with the matter, creating a high-profile vacancy at Elon Musk’s artificial intelligence startup.

    Liberatore joined xAI earlier this year and was involved in some of the company’s fundraising efforts and data center expansions in Memphis. But he left the company in July, just three months after starting, according to the Wall Street JournalBloomberg Terminal, which reported the news earlier Wednesday.

    Continue Reading

  • Tisotumab Vedotin Approved in Hong Kong for Recurrent or Metastatic Cervical Cancer

    Tisotumab Vedotin Approved in Hong Kong for Recurrent or Metastatic Cervical Cancer

    Cervical Cancer | Image
    Credit: © freshidea
    – stock.adobe.com

    The Hong Kong Department of Health has approved tisotumab vedotin-tftv (Tivdak) for use in adult patients with recurrent or metastatic cervical cancer that has progressed on or following chemotherapy, according to an announcement from Zai Lab Limited.1

    Data from the phase 3 innovaTV 301 trial (NCT04697628) showed that treatment with the antibody-drug conjugate (ADC; n = 253) led to a median overall survival (OS) of 11.5 months (95% CI, 9.8-14.9) vs 9.5 months (95% CI, 7.9-10.7) with chemotherapy (n = 249), translating to a 30% reduction in the risk of death (HR, 0.70; 95% CI, 0.54-0.89; P = .0038).2 The median progression-free survival (PFS) in the respective arms was 4.2 months (95% CI, 4.0-4.4) and 2.9 months (95% CI, 2.6-3.1; HR, 0.67; 95% CI, 0.54-0.82; P < .0001). Tisotumab vedotin elicited a confirmed objective response rate (ORR) of 17.8% (95% CI, 13.3%-23.1%) vs 5.2% (95% CI, 2.8%-8.8%) with chemotherapy (P < .0001).

    “[The] approval of Tivdak marks an important milestone for Zai Lab, further strengthening our Women’s franchise in Greater China,” Andrew Zhu, chief commercial officer, Greater China at Zai Lab, stated in a news release.1 “Treatment options for patients with recurrent or metastatic cervical cancer after initial therapy are limited. Tivdak, the first ADC therapy in cervical cancer, delivers a clinically meaningful survival benefit to patients. With our established commercial infrastructure for Zejula in Hong Kong, we are uniquely positioned to ensure Tivdak reaches patients without delay.”

    What is the trial design of innovaTV 301 examining tisotumab vedotin, and what patients with cervical cancer were included?

    The open-label, active-controlled, multicenter, randomized trial enrolled a total of 502 patients who had recurrent or metastatic cervical cancer.2 These patients previously receive 1 or 2 systemic therapy regimens in the recurrent or metastatic setting, which included chemotherapy plus or minus bevacizumab (Avastin) and/or an anti–PD-(L)1 therapy.

    Participants were randomized in a 1:1 fashion to receive 2 mg/kg of intravenous tisotumab vedotin every 3 weeks or investigator’s choice of chemotherapy, which could have comprised topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed. They were stratified based on prior bevacizumab exposure (yes vs no), prior anti–PD-(L)1 exposure (yes vs no), region (US vs Europe vs other), and ECOG performance status (0 vs 1). Treatment continued until intolerable toxicity or progressive disease. OS served as the trial’s primary end point, and other key end points included PFS and confirmed ORR.

    The median patient age was 50 years (range, 26-80) and about half were White (49%) and had an ECOG performance status of 0 (54%). Histologies included squamous cell carcinoma (63%), adenocarcinoma (32%), and adenosquamous (5%). Most patients had extrapelvic disease (90%). With regard to prior treatment, 61% received 1 previous line of systemic therapy and 38% had received 2 prior lines. All had previously received chemotherapy, and more than half (64%) had prior exposure to bevacizumab. Just under one-third (27%) of patients had prior anti–PD-(L)1 therapy. Moreover, most patients on the control arm received gemcitabine (44%), followed by pemetrexed (32%), topotecan (8%), vinorelbine (7%), and irinotecan (6%).

    What was learned about the safety profile of tisotumab vedotin ininnovaTV 301?

    Thirty-three percent of patients experienced serious adverse effects (AEs) with the ADC. AEs led to dose interruption or reduction for 39% and 30% of patients, respectively; they led to permanent treatment discontinuation for 15% of patients.

    The most common all-grade AEs experienced by at least 10% of patients who received tisotumab vedotin (n = 250) vs chemotherapy (n = 239) on the trial included peripheral neuropathy (38%, ADC; 4.2%, chemotherapy), conjunctival adverse reactions (37%; 1.7%), nausea (33%; 40%), fatigue (28%; 32%), epistaxis (26%; 2.5%), constipation (25%; 16%), decreased appetite (24%; 18%), alopecia (24%; 2.9%), diarrhea (22%; 15%), corneal adverse reactions (21%; 0%), dry eye (21%; 1.7%), hemorrhage (21%; 11%), abdominal pain (18%; 15%), vomiting (18%; 18%), pyrexia (17%; 21%), rash (17%; 16%), urinary tract infection (16%; 18%), pruritus (10%; 2.9%), and decreased weight (10%; 5%).

    The most common grade 3 or higher AEs in the ADC arm were peripheral neuropathy (6%), fatigue (6%), and urinary tract infection (5%). In the chemotherapy arm, they were urinary tract infection (8%), abdominal pain (2.5%), and hemorrhage (2.5%).

    Has tisotumab vedotin been approved for this indication in other countries?

    In April 2024, the FDA granted full approval to tisotumab vedotin for this indication based on findings from innovaTV 301.3 In a past interview with OncLive®, Keiichi Fujiwara, MD, PhD, of Saitama Medical University International Medical Center, discussed the significance of the decision for patients with recurrent or metastatic disease.4

    Subsequently, in March 2025, the Japanese Ministry of Health, Labour, and Welfare also approved the agent for advanced or recurrent cervical cancer that has progressed on or following chemotherapy, signaling the first approval of an ADC for cervical cancer in Japan.5 In April 2025, the European Commission also cleared the ADC for use as a monotherapy in this population.6

    The biologics license application seeking the approval of tisotumab vedotin is currently being reviewed by the National Medical Products Administration of China.1

    References

    1. Zai Lab announces approval of Tivdak for patients with recurrent or metastatic cervical cancer in Hong Kong. News release. Zai Lab Limited. September 1, 2025. Accessed September 3, 2025. https://ir.zailaboratory.com/news-releases/news-release-details/zai-lab-announces-approval-tivdakr-patients-recurrent-or
    2. Tivdak. Prescribing information. Seagen, Inc; 2024. Accessed September 3, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761208s007lbl.pdf
    3. FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer. FDA. April 29, 2024. Accessed September 3, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisotumab-vedotin-tftv-recurrent-or-metastatic-cervical-cancer
    4. Fujiwara K. Dr Fujiwara on the FDA approval of tisotumab vedotin for recurrent cervical cancer. April 29, 2024. Accessed September 3, 2025. https://www.onclive.com/view/dr-fujiwara-on-the-fda-approval-of-tisotumab-vedotin-for-recurrent-cervical-cancer.
    5. TIVDAK (tisotumab vedotin) approved by Japan Ministry of Health, Labour and Welfare for the treatment of advanced or recurrent cervical cancer that has progressed on or after chemotherapy. News release. March 27, 2025. Accessed September 3, 2025. https://ir.genmab.com/news-releases/news-release-details/tivdakr-tisotumab-vedotin-approved-japan-ministry-health-labour
    6. Tivdak (tisotumab vedotin) approved by European Commission for previously treated recurrent or metastatic cervical cancer. News release. Genmab. March 31, 2025. Accessed September 3, 2025. https://ir.genmab.com/news-releases/news-release-details/tivdakr-tisotumab-vedotin-approved-european-commission

    Continue Reading

  • OpenAI is hiring ‘AI-pilled’ academics to build a scientific discovery accelerator

    OpenAI is hiring ‘AI-pilled’ academics to build a scientific discovery accelerator

    Andriy Onufriyenko/Moment via Getty

    Follow ZDNET: Add us as a preferred source on Google.


    ZDNET’s key takeaways

    • OpenAI for Science was announced in a Tuesday X post.
    • Its goal is to accelerate scientific discovery through AI.
    • The post suggests GPT-5 will play a key role in the effort.

    Artificial intelligence researchers have long dreamed of automating the process of scientific discovery. Now OpenAI is setting out to turn that vision into reality.

    The company is launching an initiative called OpenAI for Science, aimed at building “the next great scientific instrument: an AI-powered platform that accelerates scientific discovery,” according to a Tuesday X post from company Chief Product Officer Kevin Weil. The timeline for the project is not yet known; Weil added in his post that more information would arrive in the coming months.

    Also: Every AI model is flunking medicine – and LMArena proposes a fix

    (Disclosure: Ziff Davis, ZDNET’s parent company, filed an April 2025 lawsuit against OpenAI, alleging it infringed Ziff Davis copyrights in training and operating its AI systems.)

    Weil, who will lead the effort, wrote that OpenAI will hire a team of “world-class” academics who are “completely AI-pilled” and “great science communicators” to join a small group of researchers already employed by the company.

    What can we expect from the project?

    Not much is known at this point about the “platform” that Weil and his fledgling team plans to build. But his X post hints at some aspects of the scientific process that OpenAI for Science might try to more effectively automate. 

    Weil wrote that GPT-5, the newest model from OpenAI, which was released last month, “is clearly a new threshold” in the ability for AI to help advance scientific progress. For example, he cited a recent theoretical physics paper in which the model was used to suggest ideas for proofs, suggesting that OpenAI for Science could eventually aim, in part, to help researchers formulate hypotheses and research methods, thereby speeding up the pace of discovery.

    Also: Patients trust AI’s medical advice over doctors – even when it’s wrong, study finds

    The emphasis on GPT-5 in Weil’s X post smacks of a sales tactic: the model has received mixed reviews since it was launched, with many users complaining that it was inferior to its predecessor, GPT-4o. By wedding GPT-5 with the company’s new scientific research program, OpenAI could be attempting to repair the model’s damaged credibility. After all, if the company can prove that GPT-5 is able to meaningfully contribute to scientific discovery — a rigorous process which requires abstract, multistep reasoning, and which could hypothetically result in practical benefits for society at large — individual users and businesses could be more inclined to trust the model with their own sensitive tasks.

    OpenAI did not immediately respond to ZDNET’s request for comment.

    While Weil didn’t mention grant-writing in his blog post, this is another area in which generative AI tools like ChatGPT could fruitfully be applied: researchers currently spend close to half (45%) of their time writing grant proposals, according to the think tank the Institute for Progress.

    Big strides

    AI has yet to discover new physical laws, cure cancer, suggest a comprehensive solution to climate change, or make any of the other major scientific breakthroughs that many artificial general intelligence true-believers think could be around the corner. Perhaps one day an AI model will be able to completely automate the scientific process, from formulating entirely new hypotheses to conducting experiments to analyzing results. But for the time being, AI’s scientific prowess is rooted in its ability to identify intricate networks of patterns from existing data. 

    Still, researchers have made some significant strides, and AI is rapidly becoming an integral tool in mainstream science.

    Also: Open AI, Anthropic invite US scientists to experiment with frontier models

    Google DeepMind CEO Demis Hassabis and Director John Jumper were awarded the Nobel Prize in Chemistry last year for their work on AlphaFold2, which uses AI to predict the structure of virtually all known proteins. The Nobel Prize in Physics last year was awarded to Geoffrey Hinton, one of the so-called “Godfathers of AI,” and physicist John Hopfield for their pioneering work on neural networks, which have become the technological framework for the current AI boom.

    AI’s mathematical abilities are also continuing to rapidly evolve. In July, OpenAI reported that one of its experimental reasoning models achieved a gold medal-level performance on the International Math Olympiad, which is widely considered to be one of the world’s most elite math competitions. Google DeepMind reported the same level of performance from its own model, Gemini 2.5 Pro.

    Want to follow my work? Add ZDNET as a trusted source on Google.


    Continue Reading

  • A spine-tingling discovery: This dinosaur had spiked body armor

    A spine-tingling discovery: This dinosaur had spiked body armor

    Fossils of the creature Spicomellus revealed elaborate body armor used to attract mates and deter rivals. Image: Matt Dempsey/The Natural History Museum, London

    A dinosaur that roamed modern-day Morocco more than 165 million years ago had a neck covered in three-foot long spikes, a weapon on its tail and bony body armor, according to researchers who unearthed the curious beast’s remains.

    The discovery of the animal Spicomellus in the Moroccan town of Boulemane painted a clearer picture of the bizarre, spiked ankylosaur, which was first described in 2021 based on the discovery of a single rib bone.

    Researchers now understand that the four-legged herbivore, which was about the size of a small car, was much more elaborately armored than originally believed, according to research published last month in the journal Nature.

    “Spicomellus had a diversity of plates and spikes extending from all over its body, including metre-long neck spikes, huge upwards-projecting spikes over the hips, and a whole range of long, blade-like spikes, pieces of armour made up of two long spikes, and plates down the shoulder,” research co-lead Susannah Maidment said in a statement to London’s Natural History Museum.

    “We’ve never seen anything like this in any animal before.”

    The Spicomellus‘ ribs were lined with fused spikes projecting outward — a feature never witnessed before in any other vertebrate, living or extinct.

    Co-lead of the project Richard Butler, a paleobiology professor at the University of Birmingham, described seeing the fossil for the first time as “spine-tingling.”

    “We just couldn’t believe how weird it was and how unlike any other dinosaur, or indeed any other animal we know of, alive or extinct,” Butler told the Natural History Museum.

    “It turns much of what we thought we knew about ankylosaurs and their evolution on its head and demonstrates just how much there still is to learn about dinosaurs,” he added.

    Researchers suggest that the Spicomellus‘ complex bone structure was used both to attract mates and deter rivals.

    Discovering that the dinosaur had such elaborate armor that possibly prioritized form as much as function set the animal apart from its predecessors, which had less, more defensive covering on their bodies.

    In addition to showy barbs along Spicomellus‘ exterior, remains of the animal’s tail also provided a stunning new detail for scientists.

    Fused vertebrae going down into its tail formed a “handle,” likely leading to a club-like weapon at the end — a detail ankylosaur scientists had previously believed not to have evolved until the Cretaceous period, millions of years later.

    “To find such elaborate armour in an early ankylosaur changes our understanding of how these dinosaurs evolved,” Maidment said.

    “It shows just how significant Africa’s dinosaurs are, and how important it is to improve our understanding of them,” she said.

    Continue Reading

  • Morrissey puts his business interests in the Smiths up for sale ‘to any interested party’ | The Smiths

    Morrissey puts his business interests in the Smiths up for sale ‘to any interested party’ | The Smiths

    Morrissey has announced that he “has no choice” but to put up for sale the entirety of his business interests in the Smiths “to any interested party/investor”.

    The deal, made in apparent seriousness on his website, Morrissey Solo, in a post titled “A Soul for Sale”, would include the band’s name and artwork, which he created, as well as his share of merchandising rights, lyrical and musical compositions, synchronisation, recordings and publishing contractual rights.

    In a statement, Morrissey wrote that he was “burnt out by any and all connections” to his former bandmates, Johnny Marr, Mike Joyce and the late Andy Rourke.

    “I have had enough of malicious associations,” he continued. “With my entire life I have paid my rightful dues to these songs and these images. I would now like to live disassociated from those who wish me nothing but ill will and destruction, and this is the only resolution.

    “The songs are me – they are no one else – but they bring with them business communications that go to excessive lengths to create as much dread and spite year after year. I must now protect myself, especially my health.”

    Serious investors, Morrissey wrote, should email eaves7760@gmail.com to inquire.

    Morrissey shares 50% of the rights to the Smiths with Marr. Whether the brand retains its value to investors without Morrissey as an active participant to help market it remains to be seen.

    The Guardian has contacted representatives for Marr and Joyce for comment.

    It is unclear what annual business communications are being referred to by Morrissey. Joyce recently announced the publication of a “no-holds-barred” memoir, The Drums, this November.

    Johnny Marr has previously said that he declined an “eye-watering” offer for the Smiths to reform. “It was a little bit about principles, but I’m not an idiot, I just think the vibe’s not right,” he said, referencing the evident political and personal differences between him and Morrissey.

    In 2024, Marr rubbished Morrissey’s claim that he had acquired the rights to the Smiths’ trademark “without any consultation”. Morrissey said that Marr owned the copyright which would allow the group to tour with a new vocalist.

    Marr said this was incorrect. A spokesperson said on his behalf: “In 2018, following an attempt by a third party to use the Smiths’ name – and upon discovery that the trademark was not owned by the band – Marr reached out to Morrissey, via his representatives, to work together in protecting the Smiths’ name.

    “A failure to respond led Marr to register the trademark himself. It was subsequently agreed with Morrissey’s lawyers that this trademark was held for the mutual benefit of Morrissey and Marr.

    “As a gesture of goodwill, in January 2024, Marr signed an assignment of joint ownership to Morrissey. Execution of this document still requires Morrissey to sign.­­­­­­­­”

    He denied that he was planning to tour under the Smiths name with a different singer, and had also turned down an offer from Warner Music Group to release a new Smiths compilation “given the number in existence”.

    Morrissey’s apparently dire situation may have been influenced by the evidently unsuccessful attempt to reform the Smiths, as well as the difficulties he has faced in releasing his 14th solo album, Bonfire of Teenagers, which remains on the backburner.

    He has previously said he was “gagged” owing to the subject of its title track, the 2017 terrorist attack on an Ariana Grande concert in Manchester that killed 22 people.

    He has been performing the song since 2022. It features lyrics about how “The silly people sing Don’t Look Back in Anger / And the morons swing and say Don’t Look Back in Anger / I can assure you I will look back in anger ’til the day I die,” a reference to the street singalongs of the Oasis track after the bombing. The song concludes with Morrissey singing “go easy on the killer”.

    He was dropped by his former label BMG in November 2020 and blamed the split on the label’s “new plans for ‘diversity’”. At the time, BMG declined to comment on whether the decision had anything to do with the musician’s contentious statements about race and sexual assault.

    Bonfire of Teenagers has been completed since May 2021. His new deal with Capitol should have seen the album released in February 2023. However, at the end of 2022, he said he had “voluntarily” split from Capitol and his management team, and claimed that the label was “holding on to” the record.

    In April 2024, he said he had bought back the rights to the record but alleged that “every major label in London” had refused it “while also admitting that it is a masterpiece”.

    He has called the record “the best album of my life” and said the “madly insane efforts to silence the album are somehow indications of its power. Otherwise, who would bother to get so overheated about an inconspicuous recluse?”

    Continue Reading

  • Chemo/Radiation Did Not Yield Increased Pelvic Malignancies in Rectal Cancer

    Chemo/Radiation Did Not Yield Increased Pelvic Malignancies in Rectal Cancer

    In patients with rectal cancer, the median OS was 12 years in the chemotherapy and radiation therapy group vs 24 years in the chemotherapy alone group.

    Concurrent chemotherapy with radiation therapy did not significantly increase the cumulative incidence of second pelvic malignancies, though it did increase the cumulative incidence of second non-pelvic malignancies compared with chemotherapy alone in patients with locally advanced rectal cancer, according to results from a study shared in the International Journal of Radiation Oncology, Biology, Physics.

    In the concurrent chemotherapy group, the 5- and 10-year cumulative incidences of second pelvic malignancy development was 2.1% (95% CI, 1.4%-3.0%) and 5.8% (95% CI, 4.2%-7.6%); in the chemotherapy alone group, the rates were 2.3% (95% CI, 0.92%-4.8%) and 4.2% (95% CI, 1.3%-9.8%), respectively. This difference did not reach statistical significance (Gray’s Test P = .3).

    A multivariable analysis showed that older age was associated with second pelvic malignancies (MV HR, 3.03; 95% CI, 1.39-6.60; P = .005), though chemotherapy alone was not significantly associated with fewer second pelvic malignancies (MV HR, 0.66; 95% CI, 0.30-1.44; P = .3).

    Intensity-modulated radiation therapy and volumetric modulated arc therapy techniques were associated with reduced risk of second pelvic malignancies vs conventional and 3D conformal radiation therapy on univariable analysis (P = .014).

    The most common second pelvic malignancies were prostate adenocarcinoma (31%; n = 23) and uterine cancer (28%; n = 21); uterine cancers were mostly serous, clear cell, or endometrioid, though 5 patients in the concurrent chemotherapy group developed carcinosarcomas.

    The 10-year cumulative incidence of non-pelvic second malignancies was 11.0% (95% CI, 9.1%-14.1%) in the concurrent chemotherapy group and 4.4% (95% CI, 2.2%-7.9%) in the chemotherapy alone group (Gray’s Test P = .017).

    Univariable analysis showed that being older than 50 was significantly associated with increased risk of second non-pelvic malignancies (HR, 2.48; 95% CI, 1.40-4.11; P ≤.001), and being male was associated with a decreased risk (HR, 0.61; 95% CI, 0.44-0.85; P = .004). Further, diabetes was associated with a second non-pelvic cancer (HR, 1.51; 95% CI, 1.05-2.19; P = .028), and abstaining from tobacco decreased the risk of second non-pelvic cancer (HR, 0.63; 95% CI, 0.43-0.91; P = .013).

    The most common second non-pelvic cancers were lung cancer (24%; n = 35), breast cancer (15%; n = 21), and hematologic malignancies (13%; n = 19). While 77% of those who developed a second non-pelvic cancer did not have a diagnosis of any other cancer, 13% did also develop a second pelvic malignancy.

    Regarding radiation dosimetry and technique, 21 patients who developed a second pelvic malignancy had a chemotherapy plan available; of the 21, 9 developed uterine cancer with a mean dose of 4800cGy (range, 4296-5087).

    The median overall survival (OS) in the concurrent chemotherapy group was 12 years (95% CI, 11-13) vs 24 years (95% CI, 15-unreached) in the chemotherapy alone cohort. The 5- and 10-year OS rates for those who received concurrent chemotherapy for rectal cancer was 78% (95% CI, 76%-80%) and 58% (95% CI, 55%-61%), respectively; in those who received chemotherapy alone, the rates were 88% (95% CI, 84%-91%) and 76% (95% CI, 70%-82%).

    The 10-year survival for those who did not develop second pelvic malignancies was 60% (95% CI, 57%-63%) vs 77% (95% CI, 67%-87%) in those who did develop a second pelvic malignancy (P = .042).

    “These data serve as a foundation for future prospective studies evaluating ways to further reduce the risk of second malignancies in high-risk patients undergoing [concurrent chemotherapy] for rectal cancer,” wrote lead study author Carla Hajj, MD, of the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center, and coauthors, in the paper. “Areas of potential investigation include personalized treatments using more modern technologies such as proton beam [radiation therapy] or MRI-based treatment deliveries, lifestyle changes, and robust survivorship programs.”

    The study included 2624 patients with locally advanced rectal cancer, of whom 460 were treated with chemotherapy without radiation therapy and 2164 received concurrent chemotherapy. The most common adjuvant chemotherapy regimens were folinic acid, fluorouracil (5FU), and oxaliplatin (FOLFOX; 60%), 5FU (32%), and capecitabine/oxaliplatin (CapeOx; 4%).

    Eligible patients had disease treated with chemotherapy with or without pelvic radiation therapy who were identified from an institutional database by Cancer Database, ICD-9/10, and ICD-0 histologic diagnosis codes for “rectum” or “rectosigmoid”.

    Patients were ineligible for participation if they had received prior pelvic radiation therapy or if their treatment was for recurrent disease.

    Second malignancies were defined as those preceding the rectal cancer diagnosis date by more than 6 months, synchronous cancers were defined as within 6 months of diagnosis, and metachronous cancers were defined as occurring between 6 months and 2 years after diagnosis. A second cancer was defined as occurring more than 2 years after diagnosis of locally advanced rectal cancer. The development of a non-pelvic cancer did not preclude capturing the diagnosis of a second pelvic cancer.

    Reference

    Tringale KR, Patel KH, Hilal L, et al. Development of second malignancies following chemotherapy with or without radiation therapy for the treatment of locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. Published online July 19, 2025. doi:10.1016/j.ijrobp.2025.07.1424

    Continue Reading